Advertisement

Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)

  • Manikandan DhanushkodiEmail author
  • Priya Iyer
  • Balasubramanian Ananthi
  • Arvind Krishnamurthy
  • K. M. Lakshmipathy
Case Report

Abstract

We report a patient with HER2-positive breast cancer with extensive bone metastasis who achieved excellent and durable response with oral etoposide.

Keywords

HER2-positive breast cancer Oral etoposide Response 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRefGoogle Scholar
  2. 2.
    Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.CrossRefGoogle Scholar
  3. 3.
    Johnston SRD, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: alternative. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:741–8.CrossRefGoogle Scholar
  4. 4.
    Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.CrossRefGoogle Scholar
  5. 5.
    Freedman RA, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:1081–9.CrossRefGoogle Scholar
  6. 6.
    Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:855–61.Google Scholar
  7. 7.
    Phillips NC. Oral etoposide. Drug Intell Clin Pharm. 1988;22:860–3.CrossRefGoogle Scholar
  8. 8.
    Panigrahy D, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med. 2010;1:739–46.CrossRefGoogle Scholar
  9. 9.
    Cabel L, et al. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. Breast Cancer Res Treat. 2019;173:397–406.CrossRefGoogle Scholar
  10. 10.
    Cameron D, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet Lond Engl. 2017;389:1195–205.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Radiation OncologyCancer Institute (WIA)ChennaiIndia
  3. 3.Surgical OncologyCancer Institute (WIA)ChennaiIndia
  4. 4.Nuclear MedicineCancer Institute (WIA)ChennaiIndia

Personalised recommendations